CA3212788A1 - Ceftibuten dosing regimens - Google Patents

Ceftibuten dosing regimens Download PDF

Info

Publication number
CA3212788A1
CA3212788A1 CA3212788A CA3212788A CA3212788A1 CA 3212788 A1 CA3212788 A1 CA 3212788A1 CA 3212788 A CA3212788 A CA 3212788A CA 3212788 A CA3212788 A CA 3212788A CA 3212788 A1 CA3212788 A1 CA 3212788A1
Authority
CA
Canada
Prior art keywords
optionally substituted
alkyl
ceftibuten
group
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3212788A
Other languages
English (en)
French (fr)
Inventor
David C. Griffith
Olga Lomovskaya
Elizabeth E. Morgan
Jeffery S. Loutit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qpex Biopharma Inc
Original Assignee
Qpex Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qpex Biopharma Inc filed Critical Qpex Biopharma Inc
Publication of CA3212788A1 publication Critical patent/CA3212788A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3212788A 2021-04-05 2022-03-31 Ceftibuten dosing regimens Pending CA3212788A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163170936P 2021-04-05 2021-04-05
US63/170,936 2021-04-05
PCT/US2022/071479 WO2022217199A1 (en) 2021-04-05 2022-03-31 Ceftibuten dosing regimens

Publications (1)

Publication Number Publication Date
CA3212788A1 true CA3212788A1 (en) 2022-10-13

Family

ID=83545863

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3212788A Pending CA3212788A1 (en) 2021-04-05 2022-03-31 Ceftibuten dosing regimens

Country Status (11)

Country Link
US (1) US20240197750A1 (enExample)
EP (1) EP4319760A4 (enExample)
JP (1) JP2024512793A (enExample)
KR (1) KR20230167077A (enExample)
CN (1) CN117157078A (enExample)
AU (1) AU2022254114A1 (enExample)
BR (1) BR112023020348A2 (enExample)
CA (1) CA3212788A1 (enExample)
MX (1) MX2023011483A (enExample)
TW (1) TW202304430A (enExample)
WO (1) WO2022217199A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017290060B2 (en) 2016-06-30 2021-07-22 Qpex Biopharma, Inc Boronic acid derivatives and therapeutic uses thereof
US12636297B2 (en) 2019-06-19 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US12637481B2 (en) 2020-03-18 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
IL297458A (en) 2020-05-05 2022-12-01 Qpex Biopharma Inc Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170252351A1 (en) * 2015-01-24 2017-09-07 Wockhardt Limited Antibacterial Compositions
AU2017290060B2 (en) * 2016-06-30 2021-07-22 Qpex Biopharma, Inc Boronic acid derivatives and therapeutic uses thereof
AU2017295866A1 (en) * 2016-07-14 2019-01-17 Achaogen, Inc. Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
SG11201901658PA (en) * 2016-09-16 2019-04-29 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds
US10085999B1 (en) * 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
WO2019093450A1 (ja) * 2017-11-10 2019-05-16 塩野義製薬株式会社 ジアザビシクロオクタン誘導体
DK3886798T3 (da) * 2018-11-29 2026-04-20 Basilea Pharmaceutica Int Ag Allschwil Kombinationssammensætninger, som omfatter en beta-lactamase-hæmmer, og anvendelser deraf
US12636297B2 (en) * 2019-06-19 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
EP4021443A1 (en) * 2019-08-29 2022-07-06 Arixa Pharmaceuticals, Inc. Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections

Also Published As

Publication number Publication date
MX2023011483A (es) 2023-10-03
US20240197750A1 (en) 2024-06-20
EP4319760A1 (en) 2024-02-14
TW202304430A (zh) 2023-02-01
WO2022217199A1 (en) 2022-10-13
CN117157078A (zh) 2023-12-01
KR20230167077A (ko) 2023-12-07
AU2022254114A1 (en) 2023-09-21
EP4319760A4 (en) 2025-01-08
BR112023020348A2 (pt) 2023-11-21
JP2024512793A (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
US20240197750A1 (en) Ceftibuten dosing regimens
WO2020259528A1 (zh) 治疗特发性肺纤维化的方法
CA3093749A1 (en) Method of treating fibrotic disease
EP1443933B1 (en) Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents
AU2020218496B2 (en) Methods for treating symptoms and disorders associated with lysosomal storage diseases
CA3087932A1 (en) Acetal compounds and therapeutic uses thereof
EP4558515A1 (en) Compositions and methods for the treatment of metabolic and liver disorders
CA2862193C (en) Antituberculosis drug combination comprising oxazole compounds
JP3208437B2 (ja) 癌転移抑制剤
JP5339840B2 (ja) 抗ｘｄｒ−ｔｂ薬、抗ｍｄｒ−ｔｂ薬、及び併用抗結核薬
CN119233823A (zh) 硼化合物治疗非结核分枝杆菌感染的方法和用途及用于治疗相同疾病的药物组合物
JP4451521B2 (ja) 難治性血管炎治療剤
EP1084704B1 (en) Remedies for spinocerebellar ataxia and compositions for treating spinocerebellar ataxia
WO2005030143A2 (en) Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
JP2016526032A (ja) ポジション（ｐｏｓｉｔｉｏｎ）放射断層撮影（ｐｅｔ）スキャンでリファキシミンを使用する方法
EP4473966A1 (en) Cancer treatment agent including malt1 inhibiting drug as active ingredient
US20040087513A1 (en) New drug combinations based on sodium channel blockers and magnesium salts
TWI736243B (zh) 二胺基嘧啶類化合物治療咳嗽的方法
US20240075041A1 (en) Treatment of eosinophilic disorders with avapritinib
CN114929224A (zh) 治疗肝性脑病的新药物
EP4591863A1 (en) Method for treating pneumoconiosis
MX2010008849A (es) Un metodo para reducir efectos secundarios en el sistema nervioso central (cns) y sistema gastrointestinal asociado con terapia de combinacion prolongada de dextrometorfano/dosis baja de quinidina.
KR20040028916A (ko) 소듐/칼슘 교환 시스템을 저해하는 약제
HK40078840A (en) Novel medicament for treating hepatic encephalopathy
CA2491217A1 (en) New drug combinations based on sodium channel blockers and magnesium salts

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241224

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241224

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260526